McEvoy GK (ed): American Hospital Formulary Service Drug Information. Bethesda, MD, American Society of Hospital Pharmacists, 1990
2.
Teicher B., Holden S., Eder J., et al: Preclinical studies relating to the use of thiotepa in the high dose setting alone and in combination. Semin Oncol17:18-32, 1990 (suppl 3)
3.
Egorin M., Snyder S.; Pan S., et al: Cellular transport and accumulation of thiotepa. Semin Oncol17:7-17, 1990 (suppl 3)
4.
Wolff S., Herzig R., Fay J., et al: High-dose N, N', N" triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation, phase I studies. Semin Oncol17:2-6, 1990 (suppl 3)
5.
Heideman R., Cole D., Balis F., et al: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: Evidence for dose-dependent plasma clearance of thiotepa. Cancer Res49:736-741, 1989
6.
Lokich J., Egom M., Cohen B., et al: A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion. Cancer63:46-50, 1989
7.
O'Dwyer P., Engstrom P., Peter R., et al: Phase V pharmacokinetic reevaluation of thiotepa. Proc Am Soc Clin Oncol7:64, 1988 (abstr)
8.
Strong J., Collins J., Lester C., et al: Pharmacolcinetics of intraventricular and intravenous N, N', N" triethylenethiophosphoramide (thiotepa) in Rhesus monkeys and humans. Cancer Res46:6101-6104, 1989
